Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

NCT04751487 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1239

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG: Itepekimab SAR440340
DRUG: Placebo

Sponsor

Sanofi

Collaborators

[object Object]